A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Generalized Myasthenia Gravis
DRUG: B007|DRUG: Placebo
Proportion of subjects：MG-ADL（Myasthenia gravis-activities of daily living profile） decreased by ≥2, Proportion of subjects：MG-ADL decreased by ≥2, Approximately 16 weeks
Proportion of subjects：subjects without SoC（Standard of Care） change and MG-ADL decreased by ≥2, Proportion of subjects：subjects without SoC change and MG-ADL decreased by ≥2, Approximately 24 weeks|Proportion of subjects：subjects without SoC change and QMG(Quantitative Myasthenia Gravis score) decreased by ≥3, Proportion of subjects：subjects without SoC change and QMG decreased by ≥3, Approximately 24 weeks|Changes in MGQoL15r (Myasthenia gravis quality of life15-item revised) from baseline., Changes in MGQoL15r from baseline., Approximately 24 weeks|Changes in MGC (Myasthenia gravis composite) from baseline., Changes in MGC from baseline, Approximately 24 weeks|Incidence of Treatment-Emergent Adverse Events, Adverse event type, incidence, duration, Approximately 1 years
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.